Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1333617

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1333617

Gene Delivery Systems

PUBLISHED:
PAGES: 196 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 14850

Add to Cart

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Gene Delivery Systems Market to Reach $5.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Gene Delivery Systems estimated at US$3.4 Billion in the year 2022, is projected to reach a revised size of US$5.6 Billion by 2030, growing at aCAGR of 6.6% over the period 2022-2030. Viral Gene, one of the segments analyzed in the report, is projected to record 7% CAGR and reach US$3.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Viral Gene segment is readjusted to a revised 6.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 6% CAGR

The Gene Delivery Systems market in the U.S. is estimated at US$1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$967.4 Million by the year 2030 trailing a CAGR of 6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 5.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5% CAGR.

Select Competitors (Total 46 Featured) -

  • Amgen, Inc.
  • Bayer AG
  • Human Stem Cells Institute
  • Johnson & Johnson
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.
Product Code: MCP16418

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Gene Delivery Systems - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for CNS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Gene Delivery Systems Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Non-Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Combined Hybrid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • JAPAN
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • CHINA
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: China 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: China 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • EUROPE
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • FRANCE
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: France 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: France 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • GERMANY
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2014, 2023 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Rest of World 16-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2014, 2023 & 2030

IV. COMPETITION

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!